Drug intelligence / Profile preview

cisplatin + Nanocis

Development stage: Unknown
Lead developer: Michigan State University
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

Cisplatin + Nanocis appears to be a combination of cisplatin, a platinum-based chemotherapeutic agent, with a nanoformulation delivery system called Nanocis. Cisplatin works by forming DNA adducts that interfere with DNA replication and transcription, ultimately leading to cell death through apoptosis. The nanoformulation likely aims to improve cisplatin's therapeutic efficacy while reducing its systemic toxicity. Nanoformulations of cisplatin have been shown to delay drug release, prolong half-life, reduce systemic toxicity, enhance cell penetration, better target cancer cells, and inhibit tumor progression.

Targets

DNA

Beyond the preview

Go deeper on cisplatin + Nanocis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + Nanocis.

Explore the full profile